Fresenius Medical Care AG & Co. KGaA (ETR:FME) received a €61.00 ($71.76) price objective from equities research analysts at Sanford C. Bernstein in a research report issued on Tuesday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Sanford C. Bernstein’s price objective suggests a potential upside of 4.52% from the company’s previous close.
FME has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft set a €65.00 ($76.47) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Thursday, February 4th. JPMorgan Chase & Co. set a €51.10 ($60.12) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a report on Friday, February 12th. Independent Research set a €76.00 ($89.41) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. Warburg Research set a €84.00 ($98.82) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Thursday, October 29th. Finally, Jefferies Financial Group set a €60.00 ($70.59) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of €70.18 ($82.56).
FME stock opened at €58.36 ($68.66) on Tuesday. Fresenius Medical Care AG & Co. KGaA has a one year low of €53.50 ($62.94) and a one year high of €79.96 ($94.07). The firm has a market cap of $17.09 billion and a PE ratio of 12.99. The firm’s 50 day moving average price is €64.87 and its 200-day moving average price is €69.21. The company has a debt-to-equity ratio of 103.14, a quick ratio of 0.71 and a current ratio of 1.11.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.